Results 71 to 80 of about 5,796 (217)

Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study [PDF]

, 2016
Michela Silvestri, Francesca Marando, Anna Maria Costanzo, Umberto di Luzio Paparatti, Giovanni A. Rossi   +4 more
openalex   +1 more source

Respiratory syncytial virus immunization patterns in Germany, 2015–2020

Human Vaccines & Immunotherapeutics
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children worldwide. Using routine statutory health insurance claims data including patients from all regions of Germany, we investigated
Moritz Wick, Roman Kliemt, Anahita Poshtiban, Nils Kossack, Gerhard-Paul Diller, Samira Soudani, Mathieu Bangert, Rolf Kramer, Oliver Damm   +8 more
doaj   +1 more source

Economic disadvantages of palivizumab [PDF]

Archives of Disease in Childhood, 2000
Editor,—We would fully agree with Dr Sanjeev Deshpande's appraisal of the economic disadvantages of palivizumab ( Arch Dis Child 2000; 82 :88–90) and …
openaire   +1 more source

Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study [PDF]

, 2019
Mahmoud Elhalik, Khaled El-Atawi, Swarup Kumar Dash, A. M. Faquih, A.D. Satyan, N. Gourshettiwar, Anis A. Khan, S. Varughese, Aravind Ramesh, E. Khamis   +9 more
openalex   +1 more source

1829 Severe Forms of Osteogenesis Imper.Fecta (OI) In Infants and the Role of Respiratory Syncitial Virus (RSV) Immunoprophylaxis with Palivizumab [PDF]

, 2012
Ranjit Philip, S M Qadri
openalex   +1 more source

GUIDELINES FOR THE USE OF SPECIFIC MONOCLONAL ANTIBODIES (PALIVIZUMAB) FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN SLOVENIA

Zdravniški Vestnik, 2002
Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in children under 12 months of age. Premature children and those with chronic lung disease are at increased risk for severe RSV infection.
Marko Pokorn, Milan Čižman, Janez Primožič, Janez Babnik, Silvo Kopriva, Zdravko Roškar   +5 more
doaj  

Palivizumab prophylaxis in haemodynamically significant congenital heart disease * Authors' reply [PDF]

, 2005
Timothy F. Feltes
openalex   +1 more source

Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group

Pediatric Health, Medicine and Therapeutics, 2014
Gerard Notario,1 Pamela Vo,2 Katherine Gooch,2 Roger Deaton,3 Xionghua Wu,4 Brian Harris,4 Parthiv J Mahadevia,4 Pablo J Sánchez51Clinical Development and Medical Affairs, 2Global Heath Economics and Outcomes Research, 3Statistics, AbbVie Inc ...
Notario G, Vo P, Gooch K, Deaton R, Wu X, Harris B, Mahadevia PJ, Sánchez PJ   +7 more
doaj  

Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries

Clinical and Developmental Immunology, 2013
Respiratory syncytial virus (RSV) infection occurs commonly in infants aged ≤2 years, and severe infection results in hospitalization with accompanying morbidity and mortality.
Bosco Paes, Ian Mitchell, Abby Li, Tetsuhiro Harimoto, Krista L. Lanctôt   +4 more
doaj   +1 more source

Medical Utilization Associated with Palivizumab Compliance in a Commercial and Managed Medicaid Health Plan [PDF]

, 2010
Jocelyn L. Diehl, Jessica R. Daw, Kim C. Coley, Renee Rayburg   +3 more
openalex   +1 more source